| Entry |
|
|---|
| Name |
Ranitidine hydrochloride (JP18/USP);
Zantac (TN) |
|---|
| Product |
|
|---|
| Generic |
RANITIDINE (Ajanta Pharma USA), RANITIDINE (Amneal Pharmaceuticals LLC), RANITIDINE (Amneal Pharmaceuticals LLC), RANITIDINE (Amneal Pharmaceuticals of New York LLC), RANITIDINE (Aphena Pharma Solutions - Tennessee), RANITIDINE (Bryant Ranch Prepack), RANITIDINE (Bryant Ranch Prepack), RANITIDINE (Bryant Ranch Prepack), RANITIDINE (Bryant Ranch Prepack), RANITIDINE (Glenmark Pharmaceuticals), RANITIDINE (Lannett Company), RANITIDINE (Medsource Pharmaceuticals), RANITIDINE (Pharmaceutical Associates), RANITIDINE (RedPharm Drug), RANITIDINE HYDROCHLORIDE (Dr. Reddy's Laboratories Limited), RANITIDINE HYDROCHLORIDE (Sandoz), RANITIDINE HYDROCHLORIDE (Zydus Lifesciences Limited), RANITIDINE HYDROCHLORIDE (Zydus Lifesciences Limited), RANITIDINE HYDROCHLORIDE (Zydus Pharmaceuticals USA), RANITIDINE HYDROCHLORIDE (Zydus Pharmaceuticals USA) |
|---|
| Formula |
C13H22N4O3S. HCl
|
|---|
| Exact mass |
350.1179
|
|---|
| Mol weight |
350.8647
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01481 Histamine receptor H2 antagonist
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
Transporter substrate
DG02854 SLC22A2 substrate
Transporter inhibitor
DG02863 SLC22A2 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 2325 |
| Product (DG00018): | D00673<JP/US> |
|
|---|
| Efficacy |
Anti-ulcerative, H2 receptor antagonist |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Transporter: SLC22A2 [HSA: 6582]
|
|---|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565], CYP3A [HSA: 1576 1577 1551]
Transporter inhibition: SLC22A2 [HSA: 6582]
|
|---|
| Structure map |
| map07227 | Histamine H2/H3 receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BA H2-receptor antagonists
A02BA02 Ranitidine
D00673 Ranitidine hydrochloride (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Histamine2 (H2) Receptor Antagonists
Ranitidine
D00673 Ranitidine hydrochloride (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
232 Peptic ulcer agents
2325 H2 blockers
D00673 Ranitidine hydrochloride (JP18/USP)
Classification of Japanese OTC drugs [BR:br08313]
Agents for digestive organs
09 Histamine H2 receptor blocker containing drugs
D00673 Ranitidine hydrochloride (JP18/USP)
Risk category of Japanese OTC drugs [BR:br08312]
First-class OTC drugs
Inorganic and organic chemicals
Ranitidine
D00673 Ranitidine hydrochloride (JP18/USP)
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01481 Histamine receptor H2 antagonist
DG00018 Ranitidine
D00673 Ranitidine hydrochloride
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00018 Ranitidine
D00673 Ranitidine hydrochloride
DG02852 CYP3A/CYP3A4 inhibitor
DG00018 Ranitidine
D00673 Ranitidine hydrochloride
Transporter substrate
DG02854 SLC22A2 substrate
DG00018 Ranitidine
D00673 Ranitidine hydrochloride
Transporter inhibitor
DG02863 SLC22A2 inhibitor
DG00018 Ranitidine
D00673 Ranitidine hydrochloride
Drug classes [BR:br08332]
Gastrointestinal agent
DG01481 Histamine receptor H2 antagonist
D00673 Ranitidine hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
HRH2
D00673 Ranitidine hydrochloride (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00673 Ranitidine hydrochloride
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00673
Drug transporters
D00673
Rx-to-OTC switch list in Japan [br08314.html]
D00673
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01481 Histamine receptor H2 antagonist
DG00018 Ranitidine
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00018 Ranitidine
DG02852 CYP3A/CYP3A4 inhibitor
DG00018 Ranitidine
Transporter substrate
DG02854 SLC22A2 substrate
DG00018 Ranitidine
Transporter inhibitor
DG02863 SLC22A2 inhibitor
DG00018 Ranitidine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 22
1 C8y C 19.1062 -21.6933
2 O2x O 20.2292 -22.5356
3 C8x C 19.5273 -20.3597
4 C1b C 17.8427 -22.3952
5 C8y C 21.3523 -21.6933
6 C8x C 20.9311 -20.3597
7 N1c N 16.6495 -21.6933
8 C1b C 22.5455 -22.3952
9 C1a C 15.4562 -22.3952
10 C1a C 16.6495 -20.2895
11 S2a S 23.7388 -21.6933
12 C1b C 25.0022 -22.3952
13 C1b C 26.1956 -21.6933
14 N1b N 27.3890 -22.3952
15 C2c C 28.5822 -21.6933
16 C2b C 29.8457 -22.3952
17 N1b N 28.5822 -20.2895
18 N2b N 31.0389 -21.6933 #+
19 C1a C 27.3890 -19.5875
20 O3a O 31.0389 -20.2895 #-
21 O3a O 32.2322 -22.3952
22 X Cl 30.1262 -25.5343
BOND 21
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 3 6 1
6 4 7 1
7 5 8 1
8 7 9 1
9 7 10 1
10 8 11 1
11 11 12 1
12 12 13 1
13 13 14 1
14 14 15 1
15 15 16 2
16 15 17 1
17 16 18 1
18 17 19 1
19 18 20 1
20 18 21 2
21 5 6 2
|
|---|
